To this end, the versatilely of GoraVir to kill despite the initiation of (STING-mediated) antiviral responses could prolong its therapeutic window and enable the flexible use of combination immunotherapy in pancreatic cancer. The gene discussed is STING1; the disease is familial pancreatic carcinoma.